GlassScriptPhysician profile
John S Poceta
NPI 1093779613
$1,994.06
in general payments reported to CMS, 2019-2025
19 companies · $462 in 2025
The $462 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $75.49 · 2021: $132 · 2022: $124 · 2023: $294 · 2024: $295 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.83 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $415.16 | 2019 | |
| Harmony Biosciences LLC | $383.86 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $278.74 | 2019-2025 | |
| Axsome Therapeutics, INC. | $185.49 | 2023-2025 | Sunosi |
| Inspire Medical Systems, INC. | $111.62 | 2023-2024 | Inspire |
| Itamar Medical INC | $98.64 | 2022-2025 | Watchpatone |
| Abbvie INC. | $80.27 | 2021-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $67.81 | 2023-2025 | Lumryz |
| Sunovion Pharmaceuticals INC. | $65.86 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $48.57 | 2023-2024 | Quviviq |
| Ucb, INC. | $41.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.31 | 2019-2025 | Ofev |
| Arbor Pharmaceuticals, INC. | $34.38 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $31.69 | 2024 | Horizant |
| Noctrix Health, INC. | $30.48 | 2025 | Nidra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.25 | 2024 | Uplizna |
| Verona Pharma, INC. | $22.85 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $19.27 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Poceta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.